At least five biotechs reported earnings last week. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) jumped 12% the day after its earnings and closed the week up 7%, adding $360 million in market value. While not yet profitable, Onyx beat the Street's 4Q12 loss per share estimate by $0.38, helped by sales of two recently approved drugs. The company reported 4Q12 revenues of $127.9 million, above the consensus estimate of $113.8 million. Onyx reported Kyprolis carfilzomib sales of $45.3M, and royalty revenues of $8.2M for Stivarga regorafenib from partner Bayer AG (Xetra:BAYN). FDA approved Kyprolis for multiple myeloma (MM) in July 2012, and approved Stivarga regorafenib for metastatic colorectal cancer (mCRC) in September 2012. Tool supplier Bruker Corp. (NASDAQ:BRKR) also beat the Street's revenue and